

# Quanterix

## Quanterix Appoints SCRUM Inc. for Simoa Distribution in Japan

*Leading life science instrumentation distributor selected to offer Simoa technology*

**Lexington, Mass. – March 16 2015** — [Quanterix Corporation](#), a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced it had appointed SCRUM, Inc., of Tokyo, Japan, as an exclusive distributor for sales and support of its Simoa technology for the research market in Japan.

“We have experienced strong demand from researchers in Japan for our Simoa technology with several Japanese researcher groups traveling to Boston to access the ultrasensitive single molecule protein detection technology in our Accelerator Lab,” said Kevin Hrusovsky, Executive Chairman and CEO at Quanterix. “We are thrilled to find a partner as strong as SCRUM to offer researchers comprehensive sales, applications and field service support locally in Japan.”

“SCRUM is extremely pleased to enter into this partnership with Quanterix. We expect to develop and maintain a mutually beneficial relationship with Quanterix and rapidly engage the life science industry in Japan,” said Mikio Fuchigami, CEO and President of SCRUM. “Simoa is a revolutionary technology which has the world’s most sensitive ELISA immunoassay. The system, the Simoa HD-1 Analyzer, has already generated significant interest in the US and Europe, and dozens of instruments have been installed since December 2013. We anticipate a similar response in Japan and are keen for the opportunity to introduce the technology to the automated ELISA market, providing Japanese researchers with the most advanced technology for their biomarker work. We will be making the first official introduction of the Simoa HD-1 Analyzer in Japan at the American Embassy in Tokyo on April 17th.”

“Our customers have been asking about Simoa for over a year now and are very eager to have the ability to measure biomarkers with far greater sensitivity than ever before,” added Fuchigami. “We expect the technology to experience the same rapid adoption in Japan as it already has in Europe and North America, and look forward to empowering researchers to create meaningful discoveries that improve human health with this revolutionary platform.”

To learn more about Simoa, please visit: <http://www.quanterix.com/simoa-is-here>.

### **About SCRUM, Inc.**

SCRUM Inc. was founded as a marketing and sales firm of foreign scientific products through joint capital investment by five companies in 1996. SCRUM brings superior value from around the world to the labs in pharmaceutical companies, diagnostic companies, universities, national institutions and other commercial biotech companies.

### **About Quanterix**

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: <http://www.quanterix.com>.

###

**Contacts:**

Nikki Festa & Caitlyn Keating

PAN Communications

617-502-4300

[quanterix@pancomm.com](mailto:quanterix@pancomm.com)